Overall Survival (OS) and Progression-Free Survival (PFS): a Complete Guide

In cancer research, the success of a treatment is not judged only by tumor shrinkage, but also by how long patients live and how their disease is controlled over time.

Clinical outcomes such as Overall Survival (OS) and Progression-Free Survival (PFS) are among the most important measures used in oncology trials to assess the real impact of therapies.

Alongside these, other endpoints like Disease-Free Survival, Event-Free Survival, and Quality of Life provide a broader understanding of patient benefit.

This blog post will explore the key clinical outcomes used in cancer research, focusing on OS and PFS, while also highlighting additional endpoints that play an essential role in evaluating cancer treatments.

Key Takeaways

• Overall Survival (OS) measures the time until death from any cause and remains the most reliable endpoint in cancer research
• Progression-Free Survival (PFS) evaluates how long a treatment can delay disease progression or death
• OS reflects the ultimate clinical benefit, while PFS provides earlier insight into treatment effectiveness
• Additional endpoints such as Disease-Free Survival, Event-Free Survival, and Quality of Life offer a more comprehensive view of patient outcomes
• The choice of endpoint depends on the type of cancer, study design, and feasibility of long-term follow-up
• OS requires longer trials and larger patient populations, whereas PFS allows faster evaluation of new therapies
• Statistical tools such as Kaplan–Meier curves and hazard ratios are essential for analyzing survival data
• No single endpoint is sufficient alone; combining multiple endpoints provides a more complete assessment of treatment benefit

What is Overall Survival (OS)?

Definition and Significance

Overall Survival (OS) refers to the time from diagnosis or the start of treatment until death from any cause.

• Considered the gold standard endpoint in oncology clinical trials
• Reflects the main goal of cancer treatment: prolonging life
• Widely accepted by regulatory agencies such as the FDA and EMA
• Provides a clear and clinically meaningful outcome

How OS is Measured in Clinical Trials

OS is evaluated using statistical methods that follow patients over time:

• Kaplan–Meier survival curves
  • Estimate survival probability at different time points
• Median Overall Survival (median OS)
  • The time point at which 50% of patients are still alive
• Hazard Ratio (HR)
  • Compares the risk of death between treatment groups
• Includes deaths from all causes
  • Makes OS comprehensive
  • May introduce influence from non-cancer-related factors

Advantages of OS as a Primary Endpoint

• Directly measures patient survival
• Not dependent on imaging or subjective assessments
• Easy to interpret and communicate

Limitations of OS

• Requires long follow-up periods
• Can be affected by subsequent treatments received after the trial
• Needs large sample sizes to detect significant differences

What is Progression-Free Survival (PFS)?

Definition and Significance

Progression-Free Survival (PFS) refers to the time from treatment initiation or randomization until disease progression or death from any cause, whichever occurs first.

• Focuses on delaying tumor growth or spread rather than overall mortality
• Commonly used as a primary endpoint in oncology trials
• Particularly useful when long follow-up for Overall Survival is not feasible
• Helps evaluate the direct effect of a treatment on disease control

How PFS is Measured in Clinical Trials

PFS is primarily assessed through imaging and standardized evaluation criteria:

• Radiological assessments
  • Typically performed using CT or MRI scans at predefined intervals
• RECIST criteria (Response Evaluation Criteria in Solid Tumors)
  • Used to define disease progression in a standardized way
• Kaplan–Meier survival curves
  • Estimate progression-free probability over time
• Median PFS
  • The time point at which 50% of patients have experienced progression or death
• Hazard Ratio (HR)
  • Compares the risk of progression or death between treatment groups
• Requires consistent timing and methodology
  • Ensures reliability and comparability of results

Advantages of PFS as an Endpoint

• Provides earlier evidence of treatment efficacy
• Shortens clinical trial duration
• Not influenced by therapies given after disease progression
• Useful in cancers where disease control improves patient outcomes and quality of life

Limitations of PFS

• Depends on imaging and investigator assessment
• Can vary based on scan frequency and evaluation criteria
• Does not always correlate with improved overall survival
• May introduce bias, especially in open-label studies

Other Common Clinical Outcomes in Cancer Research

While Overall Survival (OS) and Progression-Free Survival (PFS) remain the most frequently reported endpoints in oncology trials, several other clinical outcomes are also widely used to capture different aspects of treatment benefit. These endpoints provide complementary perspectives, especially in trials where OS is difficult to measure or where disease dynamics require more nuanced indicators.

1. Disease-Free Survival (DFS)

DFS refers to the time from treatment (often surgery or adjuvant therapy) until cancer recurrence or death from any cause. It is especially relevant in early-stage cancers where the goal is to eradicate detectable disease and prevent relapse. DFS is commonly used in adjuvant breast, colorectal, and lung cancer trials.

2. Event-Free Survival (EFS)

EFS measures the time from randomization until the occurrence of a predefined event such as disease progression, relapse, initiation of new therapy, or death. It is particularly important in hematologic malignancies (e.g., leukemias, lymphomas) where early progression or treatment failure strongly impacts prognosis.

3. Objective Response Rate (ORR)

ORR quantifies the proportion of patients who achieve a Complete Response (CR) or Partial Response (PR) according to radiological criteria (e.g., RECIST). It provides an early signal of treatment activity and is commonly used in phase II trials to justify progression to larger phase III studies.

4. Duration of Response (DoR)

DoR measures how long a tumor response (CR or PR) is maintained before progression. It has gained particular relevance in immuno-oncology, where some patients experience durable responses even if the overall response rate is modest.

5. Time to Progression (TTP)

TTP is similar to PFS but excludes deaths unrelated to cancer progression. While less commonly used today, it can be useful in specific clinical contexts where non-cancer-related mortality is high and may confound results.

6. Quality of Life (QoL) and Patient-Reported Outcomes (PROs)

Beyond tumor control and survival, modern oncology emphasizes the patient experience. QoL assessments and PROs capture the impact of treatment on symptoms, functional status, and overall well-being. These outcomes are increasingly integrated into trials, especially for palliative therapies where maintaining quality of life may be as important as prolonging it.

Choosing the Right Endpoint in Cancer Trials

Selecting the appropriate clinical endpoint is a critical decision in oncology trial design, as it directly influences regulatory approval, clinical adoption, and ultimately patient care. The choice of endpoint depends on several factors, including the cancer type, stage of disease, treatment modality, and study objectives.

Factors Influencing Endpoint Selection

• Disease setting: In early-stage cancers, DFS or EFS may be more relevant, as the primary goal is to prevent recurrence. In advanced cancers, OS and PFS are usually prioritized.
• Treatment characteristics: For immunotherapies, durable responses and DoR may be more meaningful than ORR alone, while targeted therapies may show strong effects on PFS even before OS benefits are apparent.
• Trial phase: Early-phase trials often focus on ORR and safety to provide rapid efficacy signals, while late-phase studies prioritize OS or PFS as primary endpoints.

Regulatory Perspectives

Regulatory agencies such as the FDA and EMA recognize OS as the most robust endpoint. However, PFS, DFS, and ORR are often accepted as surrogate endpoints, particularly when OS would require prohibitively long follow-up. For example, accelerated approvals are sometimes granted based on PFS or ORR data, with confirmatory OS results required in subsequent studies.

Examples of Endpoint Impact on Practice

• In adjuvant breast cancer, DFS improvements with trastuzumab led to its widespread adoption before mature OS data were available.
• In non-small cell lung cancer (NSCLC), PFS benefits from EGFR inhibitors (e.g., gefitinib, erlotinib) established their role as standard therapies despite initially modest OS improvements.
• In hematologic malignancies, EFS has been decisive in shaping frontline treatment strategies.

Balancing Scientific Rigor and Practicality
No single endpoint can universally capture treatment benefit. OS remains the most definitive measure, but it is often complemented by PFS, DFS, or QoL metrics to provide a more comprehensive assessment. A balanced approach—combining hard survival data with surrogate and patient-centered outcomes—offers the most reliable evaluation of novel therapies.

Statistical Considerations in Measuring OS and PFS

Accurate statistical analysis is essential for interpreting Overall Survival (OS) and Progression-Free Survival (PFS) results in oncology trials. Because survival data involve time-to-event outcomes rather than simple proportions, specialized statistical methods are employed to ensure robust and reliable conclusions.

1. Kaplan–Meier Survival Curves
The Kaplan–Meier method is the most commonly used approach to estimate survival probabilities over time. It accounts for censored data, i.e., patients who are still alive or progression-free at the time of analysis. Survival curves provide a visual representation of differences between treatment groups and allow calculation of median OS or PFS.

2. Hazard Ratios (HR) and Cox Proportional Hazards Model
Treatment effects are often quantified using hazard ratios (HR), which compare the risk of an event (death or progression) between two groups. An HR below 1 indicates a benefit for the experimental arm. The Cox proportional hazards model is frequently applied to adjust for baseline covariates and provide more precise estimates.

3. Confidence Intervals and P-values
Confidence intervals (CIs) around hazard ratios indicate the precision of the estimate, while p-values test the statistical significance of differences. Regulatory bodies typically require both statistical significance and clinical relevance before accepting trial results.

4. Challenges in Interpreting OS and PFS

• Immature data: Early analyses may underestimate long-term survival benefit, especially for immunotherapies that produce delayed effects.
• Crossover and post-progression therapies: Allowing patients in the control arm to switch to experimental treatment upon progression can dilute OS differences.
• Assessment bias in PFS: Imaging schedules and subjective interpretation of progression can introduce variability.

5. Alternative Statistical Approaches
In recent years, novel methods such as restricted mean survival time (RMST) and landmark analyses have been used to better capture survival benefits, particularly in settings where proportional hazards assumptions are violated.

Conclusion

Clinical outcomes such as Overall Survival (OS) and Progression-Free Survival (PFS) remain central to evaluating the efficacy of cancer therapies, providing complementary perspectives on survival and disease control. Alongside these, endpoints like DFS, EFS, ORR, DoR, and QoL enrich our understanding of patient benefit and treatment impact. The choice of endpoint depends on disease context, therapeutic strategy, and regulatory requirements, while robust statistical methods ensure meaningful interpretation of results. As oncology continues to evolve—particularly with targeted agents and immunotherapies—a multidimensional approach to outcome measurement will remain essential for advancing cancer research and improving patient care.

FAQs

References

1. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics
2. Evaluation of anticancer medicinal products – Scientific guideline: https://www.ema.europa.eu/en/evaluation-anticancer-medicinal-products-scientific-guideline
3. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
4. Kehl KL, Riely GJ, Lepisto EM, Lavery JA, Warner JL, LeNoue-Newton ML, Sweeney SM, Rudolph JE, Brown S, Yu C, Bedard PL, Schrag D, Panageas KS; American Association of Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Consortium. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. JAMA Netw Open. 2021 Jul 1;4(7):e2117547. doi: 10.1001/jamanetworkopen.2021.17547.
5. Korn RL, Crowley JJ. Overview: progression-free survival as an endpoint in clinical trials with solid tumors. Clin Cancer Res. 2013 May 15;19(10):2607-12. doi: 10.1158/1078-0432.CCR-12-2934.